Abbott Labs (ABT) Offering Possible 8.46% Return Over the Next 15 Calendar Days

This post was originally published on this site

Abbott Labs’s most recent trend suggests a bullish bias. One trading opportunity on Abbott Labs is a Bull Put Spread using a strike $120.00 short put and a strike $115.00 long put offers a potential 8.46% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $120.00 by expiration. The full premium credit of $0.39 would be kept by the premium seller. The risk of $4.61 would be incurred if the stock dropped below the $115.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Abbott Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Abbott Labs is bullish.

The RSI indicator is at 74.34 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Abbott Labs

IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
Tue, 02 Feb 2021 18:11:06 +0000
IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.

Why Abbott (ABT) Might be Well Poised for a Surge
Tue, 02 Feb 2021 17:20:05 +0000
Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Abbott’s (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes
Tue, 02 Feb 2021 15:10:03 +0000
Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
Tue, 02 Feb 2021 14:39:02 +0000
McKesson’s (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.

Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts
Tue, 02 Feb 2021 13:35:01 +0000
Omnicell’s (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.

Be Sociable, Share!

Related Posts